Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
Express Scripts
Federal Trade Commission
Daiichi Sankyo
Harvard Business School
US Army
Healthtrust
Argus Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REGORAFENIB

« Back to Dashboard

Clinical Trials for Regorafenib

Trial ID Title Status Sponsor Phase Summary
NCT01002378 The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib Completed Bayer Phase 1 An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Bayer Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Brigham and Women's Hospital Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Fox Chase Cancer Center Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Massachusetts General Hospital Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Oregon Health and Science University Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Suzanne George, MD Phase 2 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Regorafenib

Condition Name

Condition Name for Regorafenib
Intervention Trials
Metastatic Colorectal Cancer 17
Colorectal Neoplasms 16
Colorectal Cancer 11
Gastrointestinal Stromal Tumors 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Regorafenib
Intervention Trials
Colorectal Neoplasms 56
Gastrointestinal Stromal Tumors 16
Adenocarcinoma 9
Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Regorafenib

Trials by Country

Trials by Country for Regorafenib
Location Trials
United States 370
Italy 64
Germany 54
Japan 45
Canada 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Regorafenib
Location Trials
California 22
New York 21
Florida 19
Pennsylvania 17
Massachusetts 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Regorafenib

Clinical Trial Phase

Clinical Trial Phase for Regorafenib
Clinical Trial Phase Trials
Phase 4 4
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Regorafenib
Clinical Trial Phase Trials
Recruiting 67
Active, not recruiting 18
Completed 16
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Regorafenib

Sponsor Name

Sponsor Name for Regorafenib
Sponsor Trials
Bayer 68
Asan Medical Center 7
National Cancer Institute (NCI) 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Regorafenib
Sponsor Trials
Industry 106
Other 99
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Medtronic
Boehringer Ingelheim
Julphar
Express Scripts
Healthtrust
Covington
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.